Celerion
Private Company
Funding information not available
Overview
Celerion is a long-established, privately-held CRO focused on the critical early-phase segment of clinical research, including First-in-Human, SAD/MAD, and bioequivalence studies. It differentiates itself through a large global network of clinical units with over 650 beds, integrated bioanalytical laboratories, and a strong emphasis on speed and translational insights. The company serves pharmaceutical and biotech clients worldwide, offering expertise across multiple therapeutic areas to de-risk and accelerate their development pipelines. Its business model is entirely service-based, generating revenue from contracted research services.
Technology Platform
Integrated early-phase clinical research network with over 650 beds globally and co-located advanced bioanalytical laboratories for PK/PD, immunogenicity, and biomarker assays, emphasizing rapid data turnaround and translational medicine strategies.
Opportunities
Risk Factors
Competitive Landscape
Celerion competes in the specialized early-phase CRO segment against other niche players (e.g., Quotient Sciences, SGS, Frontage) and the early-phase units of large, full-service CROs like IQVIA, LabCorp, and Parexel. Differentiation is based on speed, integrated clinical/lab services, therapeutic expertise, and a global footprint for participant recruitment.